Security key
697947109
PALVELLA THERAPEUTICS, INC. - Common Stock (PVLA)
CUSIP: 697947109
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 8,525,488
- Total 13F value
- $534,466,075
- Share change
- +2,619,008
- Put/Call ratio
- 32%
- SEC-reported price per share
- $62.69
- Number of holders
- 100
- Value change
- +$183,107,977
- Number of buys
- 66
- Number of sells
- 26
- Shares outstanding
- 14,262,333
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
100
Top holders
10
PVLA full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
PALVELLA THERAPEUTICS, INC. SEC filings
PALVELLA THERAPEUTICS, INC. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 697947109
Recent filing periods:
Ownership snapshot
Top reported holders of PVLA - PALVELLA THERAPEUTICS, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Kaupinen Wes
Disclosed value leader
SUVRETTA CAPITAL MANAGEME...
Comparable rows
15/15
Latest evidence
30 Sep 2025
13D/G
13F
3/4/5
Lead comparable stake: 15%
13D/G row: Kaupinen Wes
Showing 1-6 of 15 holder rows.
Quick read
Kaupinen Wes leads the comparable SEC ownership view at 15%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Kaupinen Wes's linked filing trail.
Comparable ownership
Top 5
Kaupinen Wes
15%
SUVRETTA CAPITAL MANAGEMENT, LLC
7.4%
Samsara BioCapital, L.P.
3.1%
Dellora Investments LP
1.3%
Frazier Life Sciences Management,...
5.1%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Kaupinen Wes |
13D/G
|
15%
|
$38,555,729
1,644,869 shares
|
$0 | 13 Dec 2024 |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13D/G
13F
Company
|
7.4%
|
$51,556,256
822,400 shares
|
+$6,766,571 | 30 Sep 2025 |
| Samsara BioCapital, L.P. |
13D/G
|
3.1%
|
$8,989,600
339,743 shares
|
-$8,989,600 | 30 Jun 2025 |
| Dellora Investments LP |
13D/G
3/4/5
no longer 10% owner
|
1.3%
|
$3,306,892
141,079 shares
|
$0 | 13 Dec 2024 |
| Frazier Life Sciences Management, L.P. |
13F
Company
|
5.1%
|
$16,282,896
722,400 shares
|
— | 30 Jun 2025 |
| BVF INC/IL |
13F
Company
|
4.9%
|
$15,700,350
696,555 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
100
Shares
8,525,488
Rows available
100
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
64
Q3 2025 holders
100
Holder diff
36
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend